Evidence map›Paper›PMID 35473654›Full record

ArticleBehavior therapy2022

An Evaluation of the Body Dysmorphic Disorder Symptom Scale as a Measure of Treatment Response and Remission in Psychotherapy and Medication Trials.

Berta J Summers, Susanne S Hoeppner, Clare C Beatty, Mark A Blais, Jennifer L Greenberg, Katharine A Phillips, Sabine Wilhelm

Open access · greenAbstract read
In one paragraph

Article in Behavior therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Body dysmorphic disorder.Nature reviews. Disease primers · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Berta J SummersUniversity of North Carolina Wilmington; Massachusetts General Hospital, Harvard Medical School. Electronic address: summersb@uncw.edu.
Susanne S HoeppnerMassachusetts General Hospital, Harvard Medical School.
Clare C BeattyMassachusetts General Hospital, Harvard Medical School; Stony Brook University.
Mark A BlaisMassachusetts General Hospital, Harvard Medical School.
Jennifer L GreenbergMassachusetts General Hospital, Harvard Medical School.
Katharine A PhillipsButler Hospital and Rhode Island Hospital, Warren Alpert Medical School of Brown University; New York-Presbyterian Hospital, Weill Cornell Medical College.
Sabine WilhelmMassachusetts General Hospital, Harvard Medical School.
Massachusetts General Hospital · USHarvard University · USNew York Hospital Queens · US

Funding

1/2-CBT Versus Supportive Psychotherapy for Body Dysmorphic DisorderR01MH091078 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI WILHELM, SABINE · 2011 to 2015
$2.0M
2/2-CBT Versus Supportive Psychotherapy for Body Dysmorphic DisorderR01MH091023 · NIMH · RHODE ISLAND HOSPITAL · PI PHILLIPS, KATHARINE ANNE · 2011 to 2015
$1.6M
Pharmacotherapy Relapse Prevention in BDDR01MH072917 · NIMH · BUTLER HOSPITAL (PROVIDENCE, RI) · PI PHILLIPS, KATHARINE ANNE · 2005 to 2009
$1.5M
Pharmacotherapy Relapse Prevention in Body Dysmorphic DisorderR01MH072854 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI WILHELM, SABINE · 2005 to 2009
$1.5M
NIMH NIH HHS R01 MH072854NIMH NIH HHS R01 MH072917NIMH NIH HHS R01 MH091023NIMH NIH HHS R01 MH091078
6 · The paper itself

Abstract

The Body Dysmorphic Disorder Symptom Scale (BDD-SS) is a self-report tool that captures an array of representative behavioral and cognitive symptoms commonly displayed by individuals with BDD. The BDD-SS is regularly used among experts in the field, though its utility as a measure of treatment response has not yet been formally evaluated. Results from two clinical trials of BDD treatment were pooled from an archived database to create a sample of 220 BDD participants who received either psychosocial or medication-based interventions for BDD. We used baseline BDD-SS scores to describe psychometric properties, baseline correlations with other scales to examine the content validity of the BDD-SS, and longitudinal symptom data to evaluate capacity to detect clinically relevant change. Results indicated that the BDD-SS has good psychometric properties and is able to detect symptom change over time, although it showed lower rates of reliable change with treatment relative to the gold standard rater-administered Yale-Brown Obsessive-Compulsive Scale Modified for BDD (BDD-YBOCS). The BDD-SS offers meaningful information about treatment response in a self-report format and may be particularly useful to employ in clinical practice settings as a means of gathering symptom and treatment response data via self-report when rater-administered interviews are not feasible, although it may underestimate the extent of improvement with treatment.

Indexed as

Body Dysmorphic DisordersHumansPsychometricsPsychotherapySelf Reportbody dysmorphic disorderbody dysmorphic disorder symptom scalepsychometric validationreliable changetreatment response

Identifiers

PMID35473654
PMCPMC9046685
OpenAlexW4200590593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.